Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  Next»
    Study title: Ballmer−Weber−B−K, Gex−Collet−C, Wüthrich−B. Inhibition of histamine or allergen−induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología, Nov−Dec 1999, vol. 9, no. 6, p. 351−5.Ballmer−Weber−B−K, Gex−Collet−C, Wüthrich−B. Inhibition of histamine or allergen−induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología, Nov−Dec 1999, vol. 9, no. 6, p. 351−5.
    Active substance: ACRIVASTIN
    Study summary document link (including results):
    View full study record
    Document reference: 46229
    Study title: Ones−Ü, Tamay−Z. New oral antihistamines in pediatrics and safety of antihistamines in children. Current Medicinal Chemistry: Anti−Inflammatory and Anti−Allergy Agents. 2005, Vol/Iss /Pg. 4/5 (495−506), ISSN: 1568−0142.Ones−Ü, Tamay−Z. New oral antihistamines in pediatrics and safety of antihistamines in children. Current Medicinal Chemistry: Anti−Inflammatory and Anti−Allergy Agents. 2005, Vol/Iss /Pg. 4/5 (495−506), ISSN: 1568−0142.
    Active substance: ACRIVASTIN
    Study summary document link (including results):
    View full study record
    Document reference: 46222
    Study title: Ones−Ü, Tamay−Z. New oral antihistamines in pediatrics and safety of antihistamines in children. Current Medicinal Chemistry: Anti−Inflammatory and Anti−Allergy Agents. 2005, Vol/Iss /Pg. 4/5 (495−506), ISSN: 1568−0142.Ones−Ü, Tamay−Z. New oral antihistamines in pediatrics and safety of antihistamines in children. Current Medicinal Chemistry: Anti−Inflammatory and Anti−Allergy Agents. 2005, Vol/Iss /Pg. 4/5 (495−506), ISSN: 1568−0142.
    Active substance: ACRIVASTIN AND PSEUDOEPHEDRINE
    Study summary document link (including results):
    View full study record
    Document reference: 46231
    Study title: Clinical evaluation of a new antihistamine, buclizine hydrochloride (vibrazine).
    Active substance: Buclizine
    Study summary document link (including results): DE55G261P - Buclizine hydrochloride.pdf
    View full study record
    Document reference: 42009
    Study title: Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the counter antihistamines, ibuprofen and clemasine, Pratt, C.M., Am. J. Cardiol. 1994; 73: 346-352Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the counter antihistamines, ibuprofen and clemasine, Pratt, C.M., Am. J. Cardiol. 1994; 73: 346-352
    Active substance: CAFFEINE AND DIMENHYDRINATE
    Study summary document link (including results):
    View full study record
    Document reference: 23119
    Study title: Sedation and performance impairment of diphenhydramine and secon-generation antihistamines: a meta-analysis, Bender, B.G., J. Allergy Clin. Immunol. 2003; 111:770-776Sedation and performance impairment of diphenhydramine and secon-generation antihistamines: a meta-analysis, Bender, B.G., J. Allergy Clin. Immunol. 2003; 111:770-776
    Active substance: CAFFEINE AND DIMENHYDRINATE
    Study summary document link (including results):
    View full study record
    Document reference: 23102
    Study title: Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Delgado L F, Pferferman A, Solé D, Naspitz C K. Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, Apr 1998, vol. 80, no. 4, p. 333 7.
    Active substance: ERYTHROMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26452
    Study title: Prevention and treatment of serous otitis media with an oral antihistamine. A double−blind study in pediatric practice.Klein S W, Olson A L, Perrin J, Cunningham D, Hengerer A, Hoekelman R A, Roghmann K J. Clinical pediatrics, {Clin−Pediatr−Phila}, May 1980, vol. 19, no. 5, p. 342−7, ISSN: 0009−9228.
    Active substance: ERYTHROMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26540
    Study title: Do antihistamines impair school performance in children? Marsland TW, Newton WP. J Fam Pract. 2001 Sep;50(9):738. No abstract available.Do antihistamines impair school performance in children? Marsland TW, Newton WP. J Fam Pract. 2001 Sep;50(9):738. No abstract available.
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26199
    Study title: Marsland TW, Newton WP Do antihistamines impair school performance in children? . J Fam Pract. 2001 Sep;50(9):738. No abstract available.Marsland TW, Newton WP Do antihistamines impair school performance in children? . J Fam Pract. 2001 Sep;50(9):738. No abstract available.
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26191
    Study title: Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the counter antihistamines, ibuprofen and clemasine, Pratt, C.M., Am. J. Cardiol. 1994; 73: 346-352Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the counter antihistamines, ibuprofen and clemasine, Pratt, C.M., Am. J. Cardiol. 1994; 73: 346-352
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26219
    Study title: Seasonal allergic rhinitis and antihistamine effects on children's learning. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Ann Allergy. 1993 Aug;71(2):121-6.Seasonal allergic rhinitis and antihistamine effects on children's learning. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Ann Allergy. 1993 Aug;71(2):121-6.
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26200
    Study title: Sedation and performance impairment of diphenhydramine and secon-generation antihistamines: a meta-analysis, Bender, B.G., J. Allergy Clin. Immunol. 2003; 111:770-776Sedation and performance impairment of diphenhydramine and secon-generation antihistamines: a meta-analysis, Bender, B.G., J. Allergy Clin. Immunol. 2003; 111:770-776
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26207
    Study title: N. Huberman (1962) Clinical evaluation of an effective, new antihistamine, dimethpyrindene maleate. Medical times, 7, 725-727. N. Huberman (1962) Clinical evaluation of an effective, new antihistamine, dimethpyrindene maleate. Medical times, 7, 725-727.
    Active substance: DIMETINDENE
    Study summary document link (including results):
    View full study record
    Document reference: 26161
    Study title: USPDI Parenteral Dosage Forms, Antihistamines (Systemic) Diphenhydramine Hydrochloride Injection USP, United States Pharmacopoeia Dispensing InformationUSPDI Parenteral Dosage Forms, Antihistamines (Systemic) Diphenhydramine Hydrochloride Injection USP, United States Pharmacopoeia Dispensing Information
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26225
    Study title: Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993 Aug;71(2):121-6Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993 Aug;71(2):121-6
    Active substance: DIPHENHYDRAMINE_OR DIPHENHYDRAMINE AND CHLORHEXIDINE
    Study summary document link (including results):
    View full study record
    Document reference: 26192
    Study title: A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
    Active substance: FEXOFENADINE
    Study summary document link (including results): Fexofenadine - Study 9.pdf
    View full study record
    Document reference: 45687
    Study title: A study of an antihistamine with delayed action in the treatment of pruritic dermatoses
    Active substance: Buclizine
    Study summary document link (including results): ADPE95H2410-translation.pdf
    View full study record
    Document reference: 42011
    Study title: Clinical evaluation of a new antihistamine, buclizine hydrochloride
    Active substance: Buclizine
    Study summary document link (including results): CE61E151.pdf
    View full study record
    Document reference: 42012
    Study title: Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children
    Active substance: CETIRIZINE
    Study summary document link (including results):
    View full study record
    Document reference: 23688
    1  2  3  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 10:44:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA